Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MPM Raises $400m To Build Early-Stage Biotechs

Executive Summary

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

You may also be interested in...



Astellas Exercises Option To Acquire Potenza, For Up To $405m

Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.

Pharma R&D Legend Stoffels To Take Helm At Galapagos

The troubled Belgian biotech has pulled off a major coup in hiring Paul Stoffels, the architect of J&J's R&D successes over the last decade, as its new CEO.

Incyte Pulls Parsaclisib Files As FDA Takes Foot Off Accelerator

After discussions with the FDA, which has made its feelings clear on accelerated approvals, Incyte has concluded it cannot complete the confirmatory trials in lymphomas that would be needed on parsaclisib in time to make them worth their while.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel